1,380 assets in Cancer

Therapeutic assets addressing Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Propofol Cancer	Hong Kong Children's Hospital	P4	BB (69)
Atorvastatin Cancer	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2/3	BB (68)
Epirubicin Cancer	Zhejiang Provincial People's Hospital	P3	BB (68)
Hydromorphon Cancer	M.D. Anderson Cancer Center	P4	BB (68)
Sevoflurane Cancer	Hong Kong Children's Hospital	P4	BB (68)
Lenalidomide Cancer	CStone Pharmaceuticals	P2	BB (67)
Oxaliplatin Cancer	Sixth Affiliated Hospital, Sun Yat-sen University	P4	BB (67)
Compound Edaravone Cancer	Nanfang Hospital, Southern Medical University	P4	BB (65)
Deoxyadrenaline Cancer	Fujian Medical University Union Hospital	P4	BB (65)
Dinitrogen Monoxide Cancer	Beth Israel Deaconess Medical Center	P4	BB (65)
D-Thioctic Acid Cancer	Ain Shams University	P4	BB (65)
Exemestane Cancer	Merck Sharp & Dohme LLC	P3	BB (65)
Fentanyl Cancer	M.D. Anderson Cancer Center	P3	BB (65)
Fluorouracilum Cancer	Sixth Affiliated Hospital, Sun Yat-sen University	P3	BB (65)
Ipilimumab Cancer	7 Hills Pharma, LLC	P2	BB (65)
Pazopanib Cancer	University Hospital, Bordeaux	P4	BB (65)
Pegloticase Cancer	M.D. Anderson Cancer Center	P4	BB (65)
Shr-9839 Cancer	Shandong Suncadia Medicine Co., Ltd.	P2	BB (65)
Trametinib Cancer	Cancer Research UK	P2/3	BB (65)
Cis-Diamminedichloroplatinum Ii Cancer	InSilico Medicine Hong Kong Limited	P4	BB (64)
Irinotecan Cancer	Sixth Affiliated Hospital, Sun Yat-sen University	P3	BB (64)
Ivuxolimab Cancer	Pfizer	P3	BB (64)
Panitumumab Cancer	Amgen	P4	BB (64)
Pelabresib Cancer	Novartis Pharmaceuticals	P3	BB (64)
Brigatinib Cancer	University Health Network, Toronto	P3	B (63)
Carboplatin Cancer	Qilu Pharmaceutical Co., Ltd.	P2/3	B (63)
Cyclophosphamide Cancer	National Cancer Institute (NCI)	P3	B (63)
Etoposide Cancer	EMD Serono Research & Development Institute, Inc.	P3	B (63)
Immunoglobulin G1, Anti-(Human Vascular Endothelial Growth Factor Receptor Type Vegfr-2 Extracellular Domain) (Human Monoclonal Imc-1121B .Gamma.-Chain), Disulphide With Human Monoclonal Imc-1121B .Kappa.-Chain, Dimer Cancer	Eli Lilly and Company	P2	B (63)
Oxygen Cancer	Beth Israel Deaconess Medical Center	P4	B (63)
Toripalimab Cancer	Nanjing Immunophage Biotech Co., Ltd	P2	B (63)
Capecitabine Cancer	University of Alabama at Birmingham	P3	B (62)
Dexasone Cancer	Merck Sharp & Dohme LLC	P3	B (62)
Docetaxel Cancer	InSilico Medicine Hong Kong Limited	P3	B (62)
Nivolumab Cancer	Exelixis	P3	B (62)
Relatlimab Cancer	Bristol-Myers Squibb	P2	B (62)
Tamoxifen Cancer	Merck Sharp & Dohme LLC	P2/3	B (62)
Testosterone Undecylate Cancer	Aminex Therapeutics, Inc.	P3	B (62)
Tocilizumab Cancer	Genentech, Inc.	P3	B (62)
Vinorelbine Ditartrate Cancer	University Health Network, Toronto	P3	B (62)
Cabozantinib Cancer	Exelixis	P3	B (61)
Fludarabine Cancer	National Cancer Institute (NCI)	P2	B (61)
Midazolam Cancer	PMV Pharmaceuticals, Inc	P1/2	B (61)
Nivestim Cancer	Roswell Park Cancer Institute	P2	B (61)
Pegfilgrastim Cancer	Guangdong Provincial People's Hospital	P3	B (61)
Prednisone Cancer	Exelixis	P3	B (61)
Rasburicase Cancer	M.D. Anderson Cancer Center	P4	B (61)
Rituximab Cancer	CStone Pharmaceuticals	P2	B (61)
Axitinib Cancer	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P3	B (60)
bp102 Cancer	Shandong Suncadia Medicine Co., Ltd.	P2	B (60)

Showing 1 to 50 of 1,380 assets

PreviousPage 1 of 28Next